Celcuity Inc. Announces Key Participation in Investor Conferences
Celcuity Inc. (NASDAQ: CELC), a pioneering biotechnology company, focuses on developing targeted therapies for oncology. Recently, the Chief Executive Officer and Co-founder, Brian Sullivan, has announced exciting opportunities for investors to engage with the company at upcoming conferences. Investors will have a chance to attend one-on-one meetings and participate in fireside chats where insights into the company's strategic direction and innovations will be revealed.
Scheduled Conferences
Brian Sullivan will present at the TD Cowen 45th Annual Health Care Conference. This event is set to take place in Boston and will commence at 10:30 a.m. ET on a date in early March. Investors unable to attend in person need not worry, as a live webcast will be available for streaming online.
Following that, Mr. Sullivan will also participate in a fireside chat at the Leerink Global Healthcare Conference, also happening in Miami at 9:20 a.m. ET shortly thereafter. This series of engagements is an excellent opportunity for investors to get a closer look at Celcuity's innovative initiatives in cancer treatment.
About Celcuity's Innovations
At the heart of Celcuity's approach is its lead therapeutic candidate, gedatolisib. This medication is a potent dual inhibitor that targets the PI3K and mTOR pathways, critically important in cancer biology. What sets gedatolisib apart is its unique mechanism of action and pharmacokinetic properties. It stands to make a significant impact in the treatment of various solid tumors.
Currently, a Phase 3 clinical trial, named VIKTORIA-1, is evaluating gedatolisib in combination with fulvestrant, and possibly palbociclib, for patients suffering from HR+/HER2- advanced breast cancer. This trial is actively enrolling participants, marking a significant step forward in the fight against this challenging condition. A wealth of additional information regarding the study is available on ClinicalTrials.gov.
Looking Ahead at Future Trials
Celcuity is also planning to initiate a Phase 3 trial, VIKTORIA-2, which aims to explore gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2- advanced breast cancer. This trial is expected to begin patient enrollment in the second quarter of 2025, which shows Celcuity’s commitment to advancing cancer treatment protocols.
Corporate Headquarters and Additional Information
Celcuity operates out of Minneapolis, where it champions cutting-edge biotechnology research to develop innovative cancer therapies. Interested parties can find further details about the company and its initiatives by visiting their official website.
Contact Information
For more inquiries, stakeholders can reach out to:
Brian Sullivan, CEO
Celcuity Inc.
Email: bsullivan@celcuity.com
Phone: (763) 392-0123
Vicky Hahne
Email: vhahne@celcuity.com
For media inquiries, contact ICR Healthcare:
Patti Bank
Email: patti.bank@icrhealthcare.com
Phone: (415) 513-1284
Frequently Asked Questions
1. What is Celcuity Inc. focused on?
Celcuity Inc. focuses on developing targeted therapies specifically for cancer treatment, emphasizing innovative approaches to treat solid tumors.
2. Who will represent Celcuity at the investor conferences?
Brian Sullivan, the Chief Executive Officer and Co-founder, will represent Celcuity at the upcoming investor conferences.
3. What is the significance of gedatolisib?
Gedatolisib is Celcuity's lead therapeutic candidate and works as a dual inhibitor for cancer treatment, offering a unique mechanism of action compared to existing therapies.
4. How can investors participate in the conferences?
Investors can attend Brian Sullivan's presentations and one-on-one meetings at the events or view the live webcasts that will be made available online.
5. Where is Celcuity headquartered?
Celcuity Inc. is headquartered in Minneapolis, where it conducts its biotechnology research and development activities.
